entertainment -WSS

entertainment

author：leisure time 2025-09-29 07:35:22 - browse：2

Among the pharmaceutical companies’ many objections to the Biden administration’s drug pricing program is a set of provisions the industry says will warp how cancer drugs are developed. On Wednesday, AstraZeneca CEO Pascal Soriot proposed a new solution.

“What we were asking — and are asking now — is a very simple fix,” said Soriot at the STAT Future Summit, saying that “the impact on health care costs would be very marginal.”

The problem, executives say, is that companies developing cancer drugs today generally start small and then go big. They seek approval first in a small setting, such as patients who have exhausted all other therapies, where it’s easiest in terms of trial size and length to show a benefit. Then they go into larger settings, such as newly diagnosed patients, where studies take longer but the revenue potential is much higher.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： Making the case for fair compensation in clinical trials

WSS

Questions and answers about ramping up H5N1 bird flu vaccine

Altering the blood type of lungs raises potential for universal organs for transplants

Study finds gene variants tied to breast cancer risk in Black women

A public health expert passes on football's full body collisions for youths

Mom launches Girl Scout troop for LGBTQ youth in Texas

Readout Newsletter: Eli Lilly, AstraZeneca, Bristol Meyers Squibb

focus

entertainment

leisure time

After affirmative action ruling, medical educators look to 'holistic review'

Fentanyl is making it harder to start addiction treatment

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Timeline: Key moments in fight for gay rights

Sports medicine is finally prioritizing gender equality

H5N1 virus can be tracked in retail milk, scientists say

Activists slam private health insurers over coverage restrictions

H5N1 virus can be tracked in retail milk, scientists say

Novavax promises a turnaround & Lilly roils the obesity market

Tennessee law changes starting July 1 will restrict trans health care and fund more school safety

knowledge

Cytokinetics CEO Robert Blum is on my Worst CEO shortlist again

FDA poised to publish guidelines for clinical trial diversity

Senate panel passes drug pricing bills, but drops one PBM reform

Liver decline slowed by off

Cue Health, Covid

Readout Newsletter: H5N1 bird flu vaccine, Cytokinetics, Gilead

leisure time

focus

hotspot

hotspot